Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
Aliment Pharmacol Ther ; 49(2): 140-146, 2019 01.
Article in English | MEDLINE | ID: mdl-30589965

ABSTRACT

BACKGROUND: Proton pump inhibitors (PPIs) are widely used to treat gastro-oesophageal reflux disease (GORD). However, the onset of action is considered slow and PPIs cannot completely block acid secretion at night. A new potassium-competitive acid blocker (P-CAB) can rapidly block acid secretion. However, whether this P-CAB can relieve GORD symptoms quickly and adequately soon after starting treatment is unknown. AIM: To determine how rapidly vonoprazan and lansoprazole provide heartburn relief. METHODS: Patients (n = 32) with endoscopically confirmed erosive oesophagitis who experienced heartburn at least once a week were randomised in a double-blind manner to receive either daily vonoprazan (20 mg) or lansoprazole (30 mg) before breakfast for 14 days. Day time and night time heartburn were assessed daily throughout the study using a five-point Likert scale. The primary endpoint was the first day of complete day and night heartburn relief for at least seven consecutive days. The ethics committees of the participating institutions approved the study protocol. RESULTS: Heartburn was relieved sooner with vonoprazan than with lansoprazole (P < 0.05, log-rank test). Heartburn was completely relieved in 31.3% and 12.5% of patients on day 1 with vonoprazan and lansoprazole, respectively. Significantly more patients achieved complete nocturnal heartburn relief with vonoprazan than lansoprazole (P < 0.01). Both regimens were well tolerated. CONCLUSIONS: Complete sustained heartburn relief was achieved sooner with vonoprazan than with lansoprazole during the first week of therapy. (UMIN000018776).


Subject(s)
Esophagitis/drug therapy , Heartburn/drug therapy , Lansoprazole/therapeutic use , Proton Pump Inhibitors/therapeutic use , Pyrroles/therapeutic use , Sulfonamides/therapeutic use , Adult , Aged , Double-Blind Method , Esophagitis/diagnosis , Female , Gastroesophageal Reflux/drug therapy , Heartburn/diagnosis , Humans , Male , Middle Aged
3.
Gastroenterol Res Pract ; 2017: 4653250, 2017.
Article in English | MEDLINE | ID: mdl-29129973

ABSTRACT

OBJECTIVE: The percentage of patients with nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin- (LDA-) induced ulcers who complain of gastrointestinal symptoms has generally been considered to be low. The aim of this study was to examine and compare the symptoms and quality of life (QOL) at peptic ulcer onset. METHODS: This study involved 200 patients who were confirmed by endoscopy to be in the acute stage of gastroduodenal ulcer (A1-H1). Patients completed a self-administered questionnaire (Global Overall Symptom score and SF-8) at ulcer onset, and data were compared between NSAIDs/LDA ulcers and non-NSAIDs/LDA ulcers. RESULTS: The upper gastrointestinal symptoms score was significantly lower for patients using LDA only (20.5 ± 9.4 in the nonusing group, 19.6 ± 8.6 in the NSAIDs-only group, 16.7 ± 11.6 in the LDA-only group, and 18.5 ± 7.2 in the NSAIDs/LDA group, P < 0.05). The QOL score (physical summary) was significantly lower in the NSAID group (42.1 ± 9.9) than in the nonusing group (47.6 ± 7.6) (P < 0.05). Patients' characteristics showed no significant differences among the groups, with the exception of age. CONCLUSION: The severity of upper abdominal symptoms at peptic ulcer onset was similar between NSAID users and nonusers.

4.
Dig Dis Sci ; 62(3): 739-745, 2017 03.
Article in English | MEDLINE | ID: mdl-28083842

ABSTRACT

BACKGROUND AND AIM: Vonoprazan (VPZ) is a new oral potassium-competitive acid blocker that has recently become available. The aim of this study was to investigate the effects of VPZ on the urease activity of H. pylori as measured by the 13C-urea breath test (13C-UBT). PATIENTS AND METHODS: A total of 60 patients (26 men, 34 women; mean age 53.2 ± 13.6 years) who were diagnosed as H. pylori-positive were recruited. The patients were randomly allocated to three treatment groups: lansoprazole (LPZ) 30 mg (n = 20), VPZ 20 mg (n = 20) once daily for 3 weeks, or the control group (n = 20). The 13C-UBT was carried out at baseline and after 3 weeks of treatment, and the baseline and after treatment results then compared. Δ13C‰ ≥ 2.5‰ was considered H. pylori-positive. RESULTS: Four patients failed to complete the medication and were omitted from the analysis; data from the LPZ group (n = 18), VPZ group (n = 18), and control group (n = 20) were analyzed. The control group showed no significant change in 13C-UBT data between baseline and the completion of 3-week treatment (baseline: 26.6 ± 23.0‰, completion: 21.1 ± 13.1‰). The 13C-UBT data at week 3 were significantly decreased in both the VPZ group (baseline: 32.8 ± 22.7‰, completion: 7.6 ± 9.2‰, p = 0.0002) and the LPZ group (baseline: 41.8 ± 33.4‰; completion: 9.6 ± 8.8‰, p = 0.0006) compared to baseline. CONCLUSIONS: VPZ treatment reduced the value of UBT, warning that UBT for patients with VPZ treatment should be evaluated carefully.


Subject(s)
Helicobacter Infections , Helicobacter pylori , Lansoprazole , Pyrroles , Sulfonamides , Adult , Aged , Breath Tests/methods , Drug Monitoring/methods , Female , Helicobacter Infections/diagnosis , Helicobacter Infections/drug therapy , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Helicobacter pylori/enzymology , Humans , Lansoprazole/administration & dosage , Lansoprazole/adverse effects , Male , Middle Aged , Proton Pump Inhibitors/administration & dosage , Proton Pump Inhibitors/adverse effects , Pyrroles/administration & dosage , Pyrroles/adverse effects , Sulfonamides/administration & dosage , Sulfonamides/adverse effects , Treatment Outcome , Urease/metabolism
5.
J Clin Gastroenterol ; 45(6): e54-9, 2011 Jul.
Article in English | MEDLINE | ID: mdl-20838235

ABSTRACT

BACKGROUND AND AIMS: In the treatment of gastric cancer, argon plasma coagulation (APC) has certain merits, such as short operation time, easy procedure, and lack of serious complications compared with endoscopic mucosal resection or endoscopic submucosal dissection, suggesting that this modality may be appropriate for some patients with gastric cancer. The aim of this study was to assess the therapeutic outcomes of APC in aged and/or high-risk patients with early gastric neoplasm. PATIENTS AND METHODS: Fifty gastric neoplastic lesions (25 early gastric cancers and 25 adenomas) in patients with severe complications were treated with APC and followed up for a mean of 3.6 years (range: 0.5 to 6.6 y). The long-term outcomes of APC therapy and its efficacy as a first-line treatment were compared in patients with those lesions treated by experienced and nonexperienced endoscopists. RESULTS: Recurrence after APC therapy occurred in 5 lesions (10.0%), with an annual relapse rate of 1.8%. The mean time to recurrence was 1.5 years. The total procedure time of APC treatment was 14.5±2.6 minutes for experienced endoscopists and 16.4±2.2 minutes for nonexperienced endoscopists, with a significant time difference between the 2 groups (P<0.05). However, the outcomes did not differ by endoscopic experience. There were no serious complications, such as perforation, bleeding, or infection. CONCLUSIONS: APC therapy seems to be a safe and useful treatment for patients with early gastric neoplasm and a high risk of severe complications. Equal therapeutic outcomes were obtained by experienced and nonexperienced endoscopists.


Subject(s)
Adenocarcinoma/therapy , Argon Plasma Coagulation/methods , Stomach Neoplasms/therapy , Adenocarcinoma/complications , Adenocarcinoma/pathology , Aged , Aged, 80 and over , Endoscopy, Gastrointestinal , Female , Humans , Male , Middle Aged , Professional Competence , Risk , Stomach Neoplasms/complications , Stomach Neoplasms/pathology , Treatment Outcome
6.
Radiat Med ; 24(2): 139-42, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16715676

ABSTRACT

Spontaneous regression of hepatocellular carcinoma (HCC) is a rare phenomenon. We present herein the case of a patient with hepatocellular carcinoma with multiple lung metastases in whom malignancy spontaneously regressed after taking Pheliinus linteus Mycelium. A 79-year-old man consulted our hospital complaining of epigastric discomfort. Abdominal MRI and CT revealed a 3 cm diameter tumor in the liver, and chest CT showed numerous nodular lesions. The levels of alpha-fetoprotein (AFP) and protein induced by vitamin K deficiency or antagonist-II (PIVKA-II) were very high. We diagnosed HCC with multiple lung metastases, and no therapy was performed. Independently he took exact from Phellinus linteus Mycelium for one month, and 6 months later the tumors appeared to be in complete regression. The mechanism underlying this intriguing phenomenon remains unknown.


Subject(s)
Carcinoma, Hepatocellular/secondary , Liver Neoplasms/pathology , Lung Neoplasms/secondary , Aged , Biomarkers, Tumor/analysis , Humans , Magnetic Resonance Imaging , Male , Mitosporic Fungi , Neoplasm Regression, Spontaneous , Phytotherapy , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...